Switching From Oral Dopamine Agonists to Rotigotine
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to demonstrate safety and tolerability of switching patients with
Restless Legs Syndrome (RLS) from an oral dopamine agonist to rotigotine.
As a secondary objective, the investigators will evaluate control of RLS symptoms on
rotigotine compared to the prior oral regimen.
Phase:
Phase 4
Details
Lead Sponsor:
John Winkelman, MD, PhD
Collaborator:
UCB Pharma
Treatments:
Dopamine Dopamine Agents Dopamine Agonists N 0437 Rotigotine